title: [Borderline tumors of the ovary].
abstract: Only within the last decade we have begun to fully appreciate the natural history and biologic behaviour of borderline tumours in the ovaries. In contradiction to invasive epithelial tumours, most borderline tumours are confined to the ovary(ies) (stage I). Because the prognosis of stage I serous borderline tumours is excellent, with five-year survival rates of almost 100%, some experts are advocating that this subset should be classified as benign. Although the standard treatment for older patients is abdominal hysterectomy and bilateral salpingo-oophorectomy, many young patients who have not completed childbearing can be safely treated with unilateral salpingo-oophorectomy coupled with comprehensive surgical staging, thereby preserving their fertility potential. Another major controversy associated with borderline tumours is the clinical management of patients with advanced-stage disease or peritoneal implants. Many experts strongly believe that surgery is the only effective treatment for borderline tumours. Others routinely employ postoperative chemotherapy for at least some subset of patients with peritoneal implants. Several investigators have focused on DNA ploidy as a predictor of recurrence and survival, but their findings are conflicting.
authors: Avdeling for gynekologisk onkologi, Det Norske Radiumhospital, Oslo.
authors: C G
authors: CG
authors: Tropé
authors: M
authors: M
authors: Baekelandt
authors: T
authors: T
authors: Bjørge
authors: V
authors: V
authors: Abeler
authors: J
authors: J
authors: Kaern
mesh_terms: D018849:Controlled Clinical Trials as Topic; D005260:Female; D016147:Genes, Tumor Suppressor; D006801:Humans; D009154:Mutation; D010051:Ovarian Neoplasms / Q000175:diagnosis* / Q000235:genetics / Q000473:pathology / Q000628:therapy; D011003:Ploidies; D011379:Prognosis; D016032:Randomized Controlled Trials as Topic; D015996:Survival Rate